InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 US Autism Observational Study Underway 10 Oct 2018 8:23AM $0.068 $0.500 risen by 635.29%
$7 First Patient Dosed in Zelda Insomnia Trial 26 Sep 2018 8:24AM $0.075 $0.500 risen by 566.67%
$7 Investor Presentation - Non-deal Roadshow 25 Sep 2018 8:24AM $0.074 $0.500 risen by 575.68%
$7 Zelda Forms New Partnership to Access German Market 4 Sep 2018 8:24AM $0.077 $0.500 risen by 549.35%
$7 Appendix 4G 31 Aug 2018 5:33PM $0.078 $0.500 risen by 541.03%
$7 Appendix 4E & Financial Statements 31 Aug 2018 5:30PM $0.078 $0.500 risen by 541.03%
$7 Appendix 3B 22 Aug 2018 5:49PM $0.070 $0.500 risen by 614.29%
$7 Two Key Clinical Appointments to Medical Advisory Board 22 Aug 2018 8:14AM $0.072 $0.500 risen by 594.44%
$7 June 2018 Quarterly Report 30 Jul 2018 8:32AM $0.082 $0.500 risen by 509.76%
$7 Appendix 4C - quarterly 30 Jul 2018 8:29AM $0.082 $0.500 risen by 509.76%
$7 Initial Director's Interest Notice 16 Jul 2018 6:11PM $0.086 $0.500 risen by 481.40%
$7 Commencement of New Managing Director 16 Jul 2018 8:22AM $0.086 $0.500 risen by 481.40%
$7 Paediatric Brain Cancer Research Update 6 Jun 2018 8:21AM $0.110 $0.500 risen by 354.55%
$7 Details of Company Address 25 May 2018 4:17PM $0.110 $0.500 risen by 354.55%
$7 Appointment of Managing Director 22 May 2018 8:20AM $0.115 $0.500 risen by 334.78%
$7 March 2018 Quarterly Report 30 Apr 2018 8:37AM $0.115 $0.500 risen by 334.78%
$7 Appendix 4C - quarterly 30 Apr 2018 8:33AM $0.115 $0.500 risen by 334.78%
$7 Insomnia Clinical Trial Update-Patient Recruitment Completed 23 Apr 2018 8:20AM $0.110 $0.500 risen by 354.55%
$7 Research into Cannabinoids and Diabetes-Related Conditions 18 Apr 2018 8:23AM $0.110 $0.500 risen by 354.55%
$7 US Autism Observational Study Receives IRB Approval 13 Apr 2018 9:47AM $0.105 $0.500 risen by 376.19%
$7 Expansion of Pancreatic Cancer Research Programme 6 Mar 2018 8:20AM $0.130 $0.500 risen by 284.62%
$7 Appendix 4D & FY18 Interim Financial Report 27 Feb 2018 4:55PM $0.135 $0.500 risen by 270.37%
$7 December 2017 Quarterly Report 31 Jan 2018 8:17AM $0.120 $0.500 risen by 316.67%
$7 Appendix 4C - quarterly 31 Jan 2018 8:17AM $0.120 $0.500 risen by 316.67%
$7 Shares Begin Trading in the USA on the OTCQB Venture Market 22 Jan 2018 8:25AM $0.115 $0.500 risen by 334.78%

426 - 450 of 545 results

Page 18 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.